In a note filed with the US Securities and Exchange Commission (SEC), California’s Lyell Immunopharma sought to reassure investors that the termination of its d 25 October 2022
Thursday’s trading wiped more than 43% off the value of Talaris Therapeutics, a US cell therapy firm developing treatments in solid organ transplantation and se 21 October 2022
Gilead Sciences has won European approval for Yescarta (axicabtagene ciloleucel) for the treatment of certain adults with different kinds of large B-cell lympho 18 October 2022
Some of the most exciting medical breakthroughs in development have been picked out by the European Federation of Pharmaceutical Industries and Associations (EF 17 October 2022
A deeper look at late-stage research conducted by Biogen suggests a more positive outlook for its amyotrophic lateral sclerosis (ALS) candidate tofersen. 23 September 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.